RxDoctor Payments Data

Catherine Woods, APRN

Family · Summerville, SCNPI 1770123929

Payments from drug & device makers

$2,985in general payments, 2019–2025

Across 180 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$410
  • AbbVie$352
  • Novartis$270
  • Biohaven Pharmaceuticals, Inc.$201
  • Novo Nordisk$187
  • Acadia Pharmaceuticals Inc$153
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$2,985100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,985 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$20,010
Medicare patients
141
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide14$14,857
Albuterol Sulfate HfaAlbuterol Sulfate26$695
Atorvastatin Calcium51$518
Rosuvastatin Calcium22$471
Metoprolol Succinate22$343
Losartan Potassium28$339
Omeprazole27$262
Duloxetine Hcl11$257
Gabapentin18$227
Amlodipine Besylate48$217
Pantoprazole Sodium18$189
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav20$145
Famotidine11$139
Doxycycline Hyclate17$136
Amitriptyline Hcl15$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$17$14,85714 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$63$9718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.

Other family in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →